Roche has received US Food and Drug Administration (FDA) 510(k) clearance for its cobas eplex respiratory pathogen panel 3 (RP3), the company announced on November 2, 2026. The test detects up to 19 viruses and bacteria from a single nasopharyngeal swab. It adds Bordetella pertussis and updates its assays for influenza A and SARS-CoV-2 to cover more strains. Laboratories can choose from up to five panel configurations to match local disease prevalence and patient needs. The test needs less than one minute of hands-on time and returns results in under two hours. It runs on the automated cobas eplex system and expands on the RP2 panel, which is authorised for emergency use.

The global HER2 targeted therapies market is forecast to grow from $10.84 billion in 2025 to $11.75 billion in 2026, according to a Research and Markets report. It is expected to reach $16.34 billion by 2030, a compound annual growth rate (CAGR) of 8.6% from 2026. Demand for targeted cancer treatments, rising breast and gastric cancer rates, and wider use of monoclonal antibody therapies are driving growth. Precision oncology, broader biomarker testing, and next-generation antibody-drug conjugates should support it further. In February 2026, Boehringer Ingelheim won US Food and Drug Administration approval for HERNEXEOS (zongertinib) for HER2-mutant advanced non-small cell lung cancer. In December 2023, Pfizer bought Seagen for about $43 billion. North America led the market in 2025; Asia-Pacific is expected to grow fastest.

Roche has launched the VENTANA BAP1 (SP527) test worldwide to help diagnose mesothelioma, a rare and deadly cancer. The automated immunohistochemistry assay helps pathologists tell mesothelioma apart from other cancers, including non-small cell lung cancer, and from benign tissue growth. The test is registered as a Class I IVD with the US Food and Drug Administration and has IVDR approval as a Class C device. Roche announced the launch in Basel on October 28, 2026. Most patients are diagnosed late, with median overall survival of just 12 to 18 months. BAP1 works alongside the recently launched MTAP and Claudin-4 tests, which help preserve limited tissue samples for molecular sequencing. "Timely differential diagnosis of mesothelioma is critical to help deliver the best outcome for patients," said Matt Sause, chief executive officer of Roche Diagnostics.